August 2019, Volume 5, Issue 10

August 2019

Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.

Table of Contents

August 2019 Issue

Burnout: A Major Injury

Thursday, August 1st, 2019
In our June 2019 issue, ASH Clinical News Associate Editor Alice Ma, MD, examined the recent attention being paid to physician wellness and burnout,...

The Biggest Losers

Thursday, August 1st, 2019
(Author’s note: The other biggest losers appearing herein will remain nameless and will owe me a nice dinner for sparing them, but more on...

Bringing Cancer Center Expertise to Rural Hospitals

Thursday, August 1st, 2019
Kevin Brigle, PhD, ANP, describes an outreach program that provides rural communities with access to cancer treatment.For the past 15 years, I have run...

August 2019 Issue

ASH Directions

ASH Backs Palliative Blood Transfusions During Hospice Care, Announces 2019 Honorific and Mentor Award...

Thursday, August 1st, 2019
ASH Backs the Use of Palliative Blood Transfusions During Hospice Care for Symptom Improvement The American Society of Hematology (ASH) has announced its support...
The Society Pages

Remembering Gustave Eisemann, Cigall Kadoch Wins 2019 Wachtel Cancer Research Prize, and more

Thursday, August 1st, 2019
Remembering Gustave Eisemann (1926 – 2019) Gustave Eisemann, MD, passed away on May 26, 2019. Born in Halberstadt, Germany, Dr. Eisemann came to the U.S. in...

August 2019 Issue

MDA Blood Mobiles are dispatched around the country six days per week.

Israel and Palestine Find Common Ground in Blood Services

Thursday, August 1st, 2019
The borders between Israelis and Palestinians are among the most formidable in the world. The walls are high, the guards on both sides are...

Is Gun Control a Health Care Issue?

Thursday, August 1st, 2019
In October 2018, the American College of Physicians (ACP) clarified its stance on whether gun control should be treated as a public health issue:...

Pulling Back the Curtain: Saad Z. Usmani, MD

Thursday, August 1st, 2019
In this edition, Saad Z. Usmani, MD, talks about the art of emotional intelligence and trekking to Mount Everest base camp with his patients. Hear more...

August 2019 Issue

You Make the Call

What could provoke venous thromboembolisms in two teenaged siblings?

Thursday, August 1st, 2019
This month, Leslie J. Raffini, MD, discusses treating large venous thromboembolisms in two teenaged siblings. And don't forget to check out next month's clinical dilemma -...
You Make the Call

Readers’ Responses: What could provoke venous thromboembolisms in two teenaged siblings?

Thursday, August 1st, 2019
Here’s how readers responded to a You Make the Call question about large venous thromoembolisms in two teenaged siblings. Disclaimer: ASH does not recommend or...

August 2019 Issue

Can a Patient’s Breath Detect Post-Transplant Gastrointestinal Graft-Versus-Host Disease?

Thursday, August 1st, 2019
Analyzing the volatile organic compounds (VOCs) expelled in the breath can help clinicians detect and monitor gastrointestinal graft-versus-host disease (GI GVHD) in patients who...
Sickle cell anemia

Voxelotor Increases Hemoglobin, Decreases Hemolysis in Patients With Sickle Cell Disease

Thursday, August 1st, 2019
A report from the phase III HOPE trial found that once-daily voxelotor led to greater increases in hemoglobin (Hb) levels and larger reductions in...

Bluebird Bio Wins European Approval for Beta Thalassemia Gene Therapy

Thursday, August 1st, 2019
Bluebird Bio’s one-time gene therapy, Zynteglo, has been cleared by E.U. regulators for the treatment of beta thalassemia in patients aged 12 and older....
WIB_icon

Short, Aggressive Antibiotic Therapy Inhibits Lymphocyte Proliferation in CTCL

Thursday, August 1st, 2019
According to a study published in Blood, patients with advanced-stage cutaneous T cell lymphoma (CTCL) a short, yet aggressive, antibiotic regimen inhibited disease activity...

Opioid Manufacturer Insys Therapeutics Files for Bankruptcy

Thursday, August 1st, 2019
Insys Therapeutics filed for Chapter 11 bankruptcy protection on June 10, just days after reaching a $225 million settlement with the U.S. Department of...

Evaluating Risk of Developing Second Cancers in Patients With Ph-Negative Myeloproliferative Neoplasms

Thursday, August 1st, 2019
According to results from a nested case-control study, patients with Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms (MPNs) are at an increased risk of developing secondary...

FDA Launches Call Center for Compassionate-Use Requests

Thursday, August 1st, 2019
The FDA has launched a call center to field doctors’ requests for access to experimental cancer drugs for individual patients who have run out...

Polatuzumab Vedotin-piiq Receives FDA Approval for DLBCL

Thursday, August 1st, 2019
The FDA has approved the CD79b-directed antibody drug conjugate polatuzumab vedotin-piiq, in combination with bendamustine and rituximab (BR), to treat adults with relapsed or...

August 2019 Issue

On location

Daratumumab Combination Induces High Response Rates in AL Amyloidosis

Thursday, August 1st, 2019
In one-year follow-up data from the phase III ANDROMEDA trial, the combination of subcutaneous daratumumab with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) led to high...
On location

Erythropoietin Increases Hemoglobin and Reticulocyte Counts in Patients with Treatment-Refractory AIHA

Thursday, August 1st, 2019
In patients with autoimmune hemolytic anemia (AIHA) unresponsive to ongoing and/or prior therapies, treatment with erythropoietin (EPO) effectively increased hemoglobin (Hb) and reticulocyte counts,...
On location

Single-Agent Ibrutinib Improves Survival and Prolongs Time to Next Treatment in Early-Stage CLL

Thursday, August 1st, 2019
In the double-blind, randomized CLL12 trial, patients with treatment-naïve, early-stage chronic lymphocytic leukemia (CLL) who received single-agent ibrutinib had longer event-free survival (EFS), progression-free...
On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

Thursday, August 1st, 2019
According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis grade, transfusion dependence, and symptoms in a cohort of patients...

SHARE